Protagonist Therapeutics, Inc.

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
25.15 ^USD	+1.99%		-1.80%	+9.68%

Apr. 03	Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	MT
Mar. 26	Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data	CI

Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 2000 Growth Index

June 24, 2022 at 12:00 am EDT

Latest news about Protagonist Therapeutics, Inc.

Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	Apr. 03	MT
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data	Mar. 26	CI
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda	Mar. 18	CI
Protagonist Therapeutics' Potential Plaque Psoriasis Drug Shows High Skin Clearance Rates in Phase 2B Study	Mar. 11	MT
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis	Mar. 11	CI
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing	Mar. 04	MT
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing	Mar. 04	MT
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing	Mar. 04	MT
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating	Feb. 28	MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda	Jan. 31	DJ
Transcript : Protagonist Therapeutics, Inc. - Special Call	Jan. 31
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset	Jan. 31	CI
Transcript : Protagonist Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:45 AM	Jan. 09
Protagonist Therapeutics Insider Sold Shares Worth $1,506,000, According to a Recent SEC Filing	Dec. 15	MT
Protagonist Therapeutics Earns $10 Million Milestone Payment in Ulcerative Colitis Trial	Dec. 13	MT
Protagonist Therapeutics, Inc. Announces $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis	Dec. 13	CI
Protagonist Therapeutics, Inc. Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-To-Head Comparisons with Deucravacitinib	Nov. 27	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Protagonist Therapeutics, Inc. Announces Achievement of $50 Million Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis	Nov. 01	CI
Protagonist Therapeutics, Inc. Announces Appointment of Daniel N. Swisher, Jr. to Its Board of Director	23-10-30	CI
Capital One Starts Protagonist Therapeutics With Overweight Rating, $32 Price Target	23-10-30	MT
Protagonist Therapeutics Expects $60 Million Milestone Payments for Psoriasis, Ulcer Drug Development	23-10-09	MT
JPMorgan Lowers Protagonist Therapeutics' Price Target to $34 From $36, Keeps Overweight Rating	23-09-25	MT

Chart Protagonist Therapeutics, Inc.

Duration

Period

More charts

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Companyâs clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Companyâs Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (Î±4Î²7) specific integrin antagonist for inflammatory bowel disease (IBD).

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Protagonist Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.66 USD

Average target price

43 USD

Spread / Average Target

+74.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PROTAGONIST THERAPEUTICS, INC.	+9.68%	1.44B
IQVIA HOLDINGS INC.	+1.51%	42.59B
MODERNA, INC.	+8.57%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B

Other Biotechnology & Medical Research